Recently, the US FDA and the European Medicines Agency (EMA) have restricted the prescription of high doses of Pfizer JAK inhibitor Xeljanz (Tofacitinib citrate).

The U.S. FDA changed its permits from primary to secondary for ulcerative colitis, one of the indications for Xeljanz, in July. The EMA has a high risk of thrombotic ulcerative colitis except in the absence of an alternative in the middle of last month. They told officials that they should not use 10mg maintenance twice a day For ulcerative colitis patients with high risk of blood clots.

For ulcerative colitis where high doses must be used, patients at risk of embolism should not be started, and patients at risk should be repla